Global Long-acting Injectable Medications Supply, Demand and Key Producers, 2026-2032
Description
The global Long-acting Injectable Medications market size is expected to reach $ 23810 million by 2032, rising at a market growth of 11.3% CAGR during the forecast period (2026-2032).
Long-acting Injectable Medications are depot-forming IM/SC drug products designed to sustain therapeutic exposure for weeks to months, purpose-built for high-stakes adherence settings: serious mental illness maintenance, HIV treatment/prevention, substance-use disorders, long-term endocrine/oncologic control and contraception. For Long-acting Injectable Medications, the “operational spec” matters as much as PK: interval and loading/bridging rules, fluctuation (C_min/C_max), device and route (IM vs SC), injection volume/needle gauge, REMS/safety monitoring, cold-chain stability, and buy-and-bill reimbursement. Core platforms include oily prodrug depots (palmitate/lauroxil), PLGA microspheres, in-situ forming depots via solvent exchange (e.g., ATRIGEL, BEPO), and long-acting nanocrystal suspensions. The branded landscape is well defined: in psychiatry—Janssen’s INVEGA franchise including 6-month HAFYERA, Otsuka/Lundbeck’s ABILIFY MAINTENA, Alkermes’ ARISTADA, Teva×MedinCell’s UZEDY (monthly/bi-monthly SC risperidone), and Lilly’s ZYPREXA RELPREVV; in HIV—ViiV’s CABENUVA (cabotegravir+rilpivirine LA) and APRETUDE (cabotegravir LA PrEP); in addiction—Indivior’s SUBLOCADE and Alkermes’ VIVITROL; for contraception/endocrine-oncology—Pfizer’s Depo-Provera (DMPA), Tolmar’s ELIGARD (leuprolide, ATRIGEL), and Novartis’ SANDOSTATIN LAR (octreotide microspheres). The supply chain spans API, medical-grade polymers/excipients, sterile drug product and fill-finish (often via CDMOs), and clinic-based distribution. Recent highlights include the Oct-2025 U.S. label expansion of UZEDY to bipolar I maintenance, ongoing real-world data for HIV LA regimens through 2025, and—importantly as a transaction case—the Dec-2024 completion of Novo Holdings’ acquisition of Catalent with Novo Nordisk purchasing three fill-finish sites, reshaping global sterile capacity available to Long-acting Injectable Medications.
Long-acting Injectable Medications are trending from “long-acting” to “operationally engineered”: interval-based regimens (monthly to semi-annual) are paired with clinic workflows, late/missed-dose algorithms and oral bridging to lock in adherence; technical/regulatory design is moving toward smaller-volume SC and simplified kits without compromising exposure, while mitigating REMS/PDSS or post-injection observation burdens; on the supply side, polymer/excipient quality, aseptic control and fill-finish reproducibility drive multi-site qualification, and sector consolidation concentrates yet professionalizes capacity; coverage for PrEP and schizophrenia LAIs continues to broaden, with real-world datasets emphasizing on-time attendance, cost offsets vs daily orals, and the practicalities of health-system delivery.
This report studies the global Long-acting Injectable Medications demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Long-acting Injectable Medications, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Long-acting Injectable Medications that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Long-acting Injectable Medications total market, 2021-2032, (USD Million)
Global Long-acting Injectable Medications total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Long-acting Injectable Medications total market, key domestic companies, and share, (USD Million)
Global Long-acting Injectable Medications revenue by player, revenue and market share 2021-2026, (USD Million)
Global Long-acting Injectable Medications total market by Type, CAGR, 2021-2032, (USD Million)
Global Long-acting Injectable Medications total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Long-acting Injectable Medications market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Johnson & Johnson, Otsuka, GSK, Eli Lilly, Alkermes, Teva Pharmaceuticals, Mapi Pharma, Lupin, Amneal, Neuraxpharm, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Long-acting Injectable Medications market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Long-acting Injectable Medications Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Long-acting Injectable Medications Market, Segmentation by Type:
Second Generation
First Generation
Global Long-acting Injectable Medications Market, Segmentation by Product:
Fluphenazine
Haloperido
Decanoate
Risperidone
Others
Global Long-acting Injectable Medications Market, Segmentation by Marketing Channel:
Hospital
Clinic
Online
Global Long-acting Injectable Medications Market, Segmentation by Application:
Schizophrenia
Bipolar Disorder
HIV
Diabete
Others
Companies Profiled:
Johnson & Johnson
Otsuka
GSK
Eli Lilly
Alkermes
Teva Pharmaceuticals
Mapi Pharma
Lupin
Amneal
Neuraxpharm
Luye Pharma
Key Questions Answered
1. How big is the global Long-acting Injectable Medications market?
2. What is the demand of the global Long-acting Injectable Medications market?
3. What is the year over year growth of the global Long-acting Injectable Medications market?
4. What is the total value of the global Long-acting Injectable Medications market?
5. Who are the Major Players in the global Long-acting Injectable Medications market?
6. What are the growth factors driving the market demand?
Long-acting Injectable Medications are depot-forming IM/SC drug products designed to sustain therapeutic exposure for weeks to months, purpose-built for high-stakes adherence settings: serious mental illness maintenance, HIV treatment/prevention, substance-use disorders, long-term endocrine/oncologic control and contraception. For Long-acting Injectable Medications, the “operational spec” matters as much as PK: interval and loading/bridging rules, fluctuation (C_min/C_max), device and route (IM vs SC), injection volume/needle gauge, REMS/safety monitoring, cold-chain stability, and buy-and-bill reimbursement. Core platforms include oily prodrug depots (palmitate/lauroxil), PLGA microspheres, in-situ forming depots via solvent exchange (e.g., ATRIGEL, BEPO), and long-acting nanocrystal suspensions. The branded landscape is well defined: in psychiatry—Janssen’s INVEGA franchise including 6-month HAFYERA, Otsuka/Lundbeck’s ABILIFY MAINTENA, Alkermes’ ARISTADA, Teva×MedinCell’s UZEDY (monthly/bi-monthly SC risperidone), and Lilly’s ZYPREXA RELPREVV; in HIV—ViiV’s CABENUVA (cabotegravir+rilpivirine LA) and APRETUDE (cabotegravir LA PrEP); in addiction—Indivior’s SUBLOCADE and Alkermes’ VIVITROL; for contraception/endocrine-oncology—Pfizer’s Depo-Provera (DMPA), Tolmar’s ELIGARD (leuprolide, ATRIGEL), and Novartis’ SANDOSTATIN LAR (octreotide microspheres). The supply chain spans API, medical-grade polymers/excipients, sterile drug product and fill-finish (often via CDMOs), and clinic-based distribution. Recent highlights include the Oct-2025 U.S. label expansion of UZEDY to bipolar I maintenance, ongoing real-world data for HIV LA regimens through 2025, and—importantly as a transaction case—the Dec-2024 completion of Novo Holdings’ acquisition of Catalent with Novo Nordisk purchasing three fill-finish sites, reshaping global sterile capacity available to Long-acting Injectable Medications.
Long-acting Injectable Medications are trending from “long-acting” to “operationally engineered”: interval-based regimens (monthly to semi-annual) are paired with clinic workflows, late/missed-dose algorithms and oral bridging to lock in adherence; technical/regulatory design is moving toward smaller-volume SC and simplified kits without compromising exposure, while mitigating REMS/PDSS or post-injection observation burdens; on the supply side, polymer/excipient quality, aseptic control and fill-finish reproducibility drive multi-site qualification, and sector consolidation concentrates yet professionalizes capacity; coverage for PrEP and schizophrenia LAIs continues to broaden, with real-world datasets emphasizing on-time attendance, cost offsets vs daily orals, and the practicalities of health-system delivery.
This report studies the global Long-acting Injectable Medications demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Long-acting Injectable Medications, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Long-acting Injectable Medications that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Long-acting Injectable Medications total market, 2021-2032, (USD Million)
Global Long-acting Injectable Medications total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Long-acting Injectable Medications total market, key domestic companies, and share, (USD Million)
Global Long-acting Injectable Medications revenue by player, revenue and market share 2021-2026, (USD Million)
Global Long-acting Injectable Medications total market by Type, CAGR, 2021-2032, (USD Million)
Global Long-acting Injectable Medications total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Long-acting Injectable Medications market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Johnson & Johnson, Otsuka, GSK, Eli Lilly, Alkermes, Teva Pharmaceuticals, Mapi Pharma, Lupin, Amneal, Neuraxpharm, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Long-acting Injectable Medications market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Long-acting Injectable Medications Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Long-acting Injectable Medications Market, Segmentation by Type:
Second Generation
First Generation
Global Long-acting Injectable Medications Market, Segmentation by Product:
Fluphenazine
Haloperido
Decanoate
Risperidone
Others
Global Long-acting Injectable Medications Market, Segmentation by Marketing Channel:
Hospital
Clinic
Online
Global Long-acting Injectable Medications Market, Segmentation by Application:
Schizophrenia
Bipolar Disorder
HIV
Diabete
Others
Companies Profiled:
Johnson & Johnson
Otsuka
GSK
Eli Lilly
Alkermes
Teva Pharmaceuticals
Mapi Pharma
Lupin
Amneal
Neuraxpharm
Luye Pharma
Key Questions Answered
1. How big is the global Long-acting Injectable Medications market?
2. What is the demand of the global Long-acting Injectable Medications market?
3. What is the year over year growth of the global Long-acting Injectable Medications market?
4. What is the total value of the global Long-acting Injectable Medications market?
5. Who are the Major Players in the global Long-acting Injectable Medications market?
6. What are the growth factors driving the market demand?
Table of Contents
121 Pages
- 1 Supply Summary
- 2 Demand Summary
- 3 World Long-acting Injectable Medications Companies Competitive Analysis
- 4 United States VS China VS Rest of World (by Headquarter Location)
- 5 Market Analysis by Type
- 6 Market Analysis by Product
- 7 Market Analysis by Marketing Channel
- 8 Market Analysis by Application
- 9 Company Profiles
- 10 Industry Chain Analysis
- 11 Research Findings and Conclusion
- 12 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
